Related references
Note: Only part of the references are listed.The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study
Y. Hozumi et al.
ANNALS OF ONCOLOGY (2011)
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03
Shozo Ohsumi et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
Cornelis J. H. van de Velde et al.
LANCET (2011)
The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer
Kenji Shibuta et al.
BREAST CANCER (2011)
Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy
T. Aihara et al.
ONCOLOGY (2010)
Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study
Christina M. Schilder et al.
ACTA ONCOLOGICA (2009)
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
V. Ziller et al.
ANNALS OF ONCOLOGY (2009)
Menopausal symptoms and adjuvant therapy-associated adverse events
P. Hadji
ENDOCRINE-RELATED CANCER (2008)
Advances in adjuvant endocrine therapy for postmenopausal women
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Norman Williams
LANCET ONCOLOGY (2008)
Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
William R. Miller et al.
ONCOLOGIST (2008)
Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response
M. P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a tamoxifen exemestane adjuvant Multicenter trial substudy
Stephen E. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 study
Manfred Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Tamoxifen treatment and new-onset depression in breast cancer patients
Kelly C. Lee et al.
PSYCHOSOMATICS (2007)
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes et al.
LANCET (2007)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quality of life of postmenopausal women in the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer
David Cella et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer
B. Moy et al.
ANNALS OF ONCOLOGY (2006)
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial
A. Buzdar et al.
LANCET ONCOLOGY (2006)
Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer
LJ Fallowfield et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women
TJ Whelan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
M Ingelman-Sundberg
PHARMACOGENOMICS JOURNAL (2005)
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
L Fallowfield et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer
N Tchen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
PE Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - Results of the ATAC (arimidex, tamoxifen alone or in comhination) trial efficacy and safety update analyses
CANCER (2003)
Emerging role of aromatase inhibitors in the adjuvant setting
PE Goss
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2003)
Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups
NE Avis et al.
SOCIAL SCIENCE & MEDICINE (2001)
Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese
H Fumimoto et al.
QUALITY OF LIFE RESEARCH (2001)
Share Paper
